GlassScriptPhysician profile
Ashley Broyles
NPI 1790202828
$3,036.29
in general payments reported to CMS, 2019-2025
30 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $800 · 2022: $746 · 2023: $502 · 2024: $529 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.53 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,078.74 | 2021-2025 | |
| Novo Nordisk INC | $434.48 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $271.70 | 2021-2025 | |
| Amgen INC. | $238.43 | 2021-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $137.93 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $137.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.91 | 2021-2025 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $69.57 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.06 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $52.18 | 2023-2024 | Opsumit, Uptravi |
| Currax Pharmaceuticals LLC | $47.46 | 2021 | |
| Abbott Laboratories | $40.00 | 2021-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $37.24 | 2025 | Watchman Flx |
| Esperion Therapeutics, INC. | $30.19 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.82 | 2022-2023 | Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $27.73 | 2023 | Azstarys |
| Impulse Dynamics (USA) INC. | $23.07 | 2023 | Optimizer |
| Philips North America LLC | $21.81 | 2024 | (Ck6) Holter |
| Seqirus USA INC | $20.61 | 2025 | Flucelvax, Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $19.72 | 2023 | |
| Antares Pharma, INC. | $17.63 | 2024 | Xyosted |
| Dexcom, INC. | $16.59 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.68 | 2023 | Rexulti |
| Edwards Lifesciences Corporation | $15.10 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $14.55 | 2022 | |
| Eisai INC. | $13.97 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.02 | 2021 | |
| Genentech USA, INC. | $11.93 | 2021 | |
| Astellas Pharma US INC | $11.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Broyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.